| Detected | Trial | Change |
|---|---|---|
| 2026-05-27 | NCT06607185 A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors |
Trial sites reduced: 56 -> 47 locations |
| 2026-05-15 | NCT07432295 Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive… |
Trial sites expanded: 3 -> 6 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT03017326 | Paediatric Hepatic International Tumour Trial | Hepatoblastoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT05358548 | ATATcH Alternating Treatment Plans for Advanced Cancer | Head and Neck Cancer | Recruiting |
| NCT07432295 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive… | Solid Tumor | Recruiting |
| NCT03323463 | Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal… | HPV-Associated Oropharyngeal Squamous Cell Carcinoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT04689347 | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable… | Metastatic Colorectal Cancer | Recruiting |
| Phase 1 | |||
| NCT06607185 | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | Pancreatic Ductal Adenocarcinoma | Active, Not Recruiting |